The Globe and Mail reports in its Saturday, Oct. 1, edition that RBC analyst Gregory Renza, after hosting a road show with Bellus Health's management on Thursday, elevated his share target to $21 (U.S.) from $19 (U.S.). The Globe's David Leeder writes that Mr. Renza rates Bellus Health "outperform." Analysts on average target the shares at $18.88 (U.S.). Mr. Renza says in a note: "With the upcoming ph.III initiation [for BLU-5937], we see heavy news flow over 2H2022/2023 -- Shionogi R&D Day, BLU KOL Day, MRK regulatory and commercial updates, validation work, SOOTHE publication -- all on top of company execution, providing read-through and momentum ahead of topline in 2H2024. We are making several model tweaks to reflect the latest patient population data and our thinking around market penetration given the latest positioning for BLU and P2X3 class in the chronic cough space." The Globe reported on Oct. 19, 2021, and Dec. 8, 2021, that Mr. Renza continued to rank Bellus Health "outperform." It was then worth $6.10 (Canadian) and $5.89 (Canadian). The Globe reported on Dec. 18, 2021, that Mr. Renza was still sticking with his "outperform" call when the shares were going for $10.12 (Canadian).